share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4:持股变动声明-高管 Kulkarni Samarth

SEC announcement ·  02/21 17:52
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
根据美国证券交易委员会的最新文件,CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼于2024年2月20日完成了6,370股普通股的出售。这些股票以每股79.67美元的价格出售,总价值约为507,498美元。在此次出售之前,库尔卡尼根据一项被归类为行使或转换衍生证券的交易,于2024年2月18日行使了期权收购了13,250股股票。在这些交易之后,库尔卡尼直接持有该公司194,257股股份。此外,库尔卡尼通过间接控股实体库尔卡尼2023 GRAT拥有20万股股票的间接实益所有权。
根据美国证券交易委员会的最新文件,CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼于2024年2月20日完成了6,370股普通股的出售。这些股票以每股79.67美元的价格出售,总价值约为507,498美元。在此次出售之前,库尔卡尼根据一项被归类为行使或转换衍生证券的交易,于2024年2月18日行使了期权收购了13,250股股票。在这些交易之后,库尔卡尼直接持有该公司194,257股股份。此外,库尔卡尼通过间接控股实体库尔卡尼2023 GRAT拥有20万股股票的间接实益所有权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息